Page last updated: 2024-08-08 00:36:42
Nonstructural protein 5A
[no definition available]
Synonyms
Research
Bioassay Publications (22)
| Timeframe | Studies on this Protein(%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 18 (81.82) | 24.3611 |
| 2020's | 4 (18.18) | 2.80 |
Compounds (8)
Drugs with Inhibition Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| bms-790052 | | IC50 | 0.0000 | 2 | 2 |
| ledipasvir | | IC50 | 0.0310 | 2 | 2 |
Drugs with Activation Measurements
Drugs with Other Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| mk-8742 | | EC90 | 0.0073 | 25 | 25 |
The Discovery of Conformationally Constrained Bicyclic Peptidomimetics as Potent Hepatitis C NS5A Inhibitors.ACS medicinal chemistry letters, , Nov-11, Volume: 12, Issue:11, 2021
Orally bioavailable HCV NS5A inhibitors of unsymmetrical structural class.Bioorganic & medicinal chemistry letters, , 09-01, Volume: 30, Issue:17, 2020
GSK2818713, a Novel Biphenylene Scaffold-Based Hepatitis C NS5A Replication Complex Inhibitor with Broad Genotype Coverage.Journal of medicinal chemistry, , 04-23, Volume: 63, Issue:8, 2020
Discovery of a novel unsymmetrical structural class of HCV NS5A inhibitors with low picomolar antiviral activity.Bioorganic & medicinal chemistry letters, , 03-01, Volume: 30, Issue:5, 2020
Discovery and Characterization of Potent Pan-Genotypic HCV NS5A Inhibitors Containing Novel Tricyclic Central Core Leading to Clinical Candidate.Journal of medicinal chemistry, , 12-12, Volume: 62, Issue:23, 2019
In Praise of Remarkably Powerful Centamolecular Therapeutic Agents.ACS medicinal chemistry letters, , Aug-08, Volume: 10, Issue:8, 2019
A novel, potent, and orally bioavailable thiazole HCV NS5A inhibitor for the treatment of hepatitis C virus.European journal of medicinal chemistry, , Apr-01, Volume: 167, 2019
Scaffold hybridization strategy towards potent hydroxamate-based inhibitors of MedChemComm, , Jun-01, Volume: 10, Issue:6, 2019
Synthesis and evaluation of novel potent HCV NS5A inhibitors.Bioorganic & medicinal chemistry letters, , Jul-15, Volume: 22, Issue:14, 2012
Highlights of the Structure-Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530).Journal of medicinal chemistry, , 05-10, Volume: 61, Issue:9, 2018
Design, synthesis and identification of silicon-containing HCV NS5A inhibitors with pan-genotype activity.European journal of medicinal chemistry, , Mar-25, Volume: 148, 2018
Discovery and Characterization of Potent Pan-Genotypic HCV NS5A Inhibitors Containing Novel Tricyclic Central Core Leading to Clinical Candidate.Journal of medicinal chemistry, , 12-12, Volume: 62, Issue:23, 2019
[no title available]Bioorganic & medicinal chemistry letters, , 08-15, Volume: 29, Issue:16, 2019
Discovery of novel pan-genotypic HCV NS5A inhibitors containing a novel tetracyclic core.Bioorganic & medicinal chemistry letters, , 03-01, Volume: 29, Issue:5, 2019
Discovery of MK-6169, a Potent Pan-Genotype Hepatitis C Virus NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Substitutions.Journal of medicinal chemistry, , 05-10, Volume: 61, Issue:9, 2018
Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms.Journal of medicinal chemistry, , 01-12, Volume: 60, Issue:1, 2017
Alkyl substituted aminal derivatives of HCV NS5A inhibitor MK-8742.Bioorganic & medicinal chemistry letters, , 08-01, Volume: 26, Issue:15, 2016
Alternative core development around the tetracyclic indole class of HCV NS5A inhibitors.Bioorganic & medicinal chemistry letters, , 10-15, Volume: 26, Issue:20, 2016
Substituted tetracyclic indole core derivatives of HCV NS5A inhibitor MK-8742.Bioorganic & medicinal chemistry letters, , 10-01, Volume: 26, Issue:19, 2016
Matched and mixed cap derivatives in the tetracyclic indole class of HCV NS5A inhibitors.Bioorganic & medicinal chemistry letters, , 08-15, Volume: 26, Issue:16, 2016